Press release
Uveitis Market: Growing Patient Pool and Biologic Advances Drive Growth to 2034
Uveitis Market: Growing Patient Pool and Biologic Advances Drive Growth to 2034
Rising autoimmune disorders, new biologic therapies, and AI-based ophthalmology platforms are driving growth in the global uveitis patient pool and transforming disease management.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72310
Introduction
The Uveitis Market is gaining strong clinical and economic momentum as global patient awareness, early diagnosis, and biologic drug innovation accelerate.
Valued at USD 510 million in 2024, the market is expected to reach USD 980 million by 2034, growing at a CAGR of 6.7%.
Uveitis - an inflammation of the uveal tract affecting the iris, ciliary body, and choroid - remains a leading cause of preventable blindness worldwide. Enhanced screening protocols, multidisciplinary care models, and data-driven patient-pool analytics are enabling earlier detection and improving long-term outcomes.
Key Players in the Market
The competitive landscape involves ophthalmic drug developers, biologics specialists, and diagnostic-imaging leaders.
Prominent players include:
• AbbVie Inc.
• Novartis AG
• Roche Holding AG
• Johnson & Johnson Vision Care Inc.
• Sun Pharmaceutical Industries Ltd.
• Santen Pharmaceutical Co. Ltd.
• Bausch Health Companies Inc.
• Regeneron Pharmaceuticals Inc.
• Allergan plc
• Pfizer Inc.
These firms are expanding portfolios with TNF-alpha inhibitors, interleukin blockers, and steroid-sparing biologics designed to control chronic and recurrent uveitis with fewer side effects.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/72310/uveitis-patient-pool-analysis-market
Key Events in the Last Five Years
• 2020 - 2021: Increased integration of ophthalmic imaging AI for faster detection of posterior uveitis.
• 2022: AbbVie launched Humira biosimilars in multiple markets, expanding access to biologic immunotherapy.
• 2023: Novartis introduced Beovu® (brolucizumab) studies targeting uveitic macular edema.
• 2024: Multinational registries and big-data analytics initiatives improved understanding of patient demographics and treatment responses globally.
Market Growth Rate
According to Exactitude Consultancy, the global uveitis patient pool is projected to grow by over 4.5% annually, supporting a CAGR of 6.7% in therapy demand.
Growth factors include:
• Rising prevalence of autoimmune diseases such as sarcoidosis and ankylosing spondylitis.
• Improved diagnostic access in emerging regions.
• Expansion of biologic and biosimilar approvals across key markets.
• Government and NGO-led screening programs to reduce vision loss.
Market Segments and Growth Analysis
The uveitis market is segmented by disease type, treatment, and region.
By Disease Type:
• Anterior Uveitis
• Intermediate Uveitis
• Posterior Uveitis
• Panuveitis
By Treatment:
• Corticosteroids (Topical, Oral, Intravitreal)
• Immunosuppressants (Methotrexate, Azathioprine)
• Biologic Agents (Adalimumab, Infliximab, Tocilizumab)
• Surgical & Adjunctive Therapies
By Region:
• North America: Dominates with strong biologic adoption and reimbursement support.
• Europe: Increasing prevalence tracking through national registries in Germany, Italy, and France.
• Asia Pacific: Fastest-growing region owing to rising autoimmune disease incidence and clinical-trial investments in Japan and India.
• Latin America & MEA: Expanding diagnostic infrastructure and affordable biosimilar access.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72310
Key Market Drivers
1. Precision Biologic Therapies:
Next-generation monoclonal antibodies and IL-6 blockers reduce recurrence and improve visual prognosis.
2. AI & Big-Data Epidemiology:
Automated image analytics and population-level databases improve disease modeling and healthcare planning.
3. Increasing Global Patient Pool:
Broader screening and better awareness have expanded the diagnosed base in both developed and emerging economies.
4. Shift Toward Long-Term Immunomodulation:
Physicians increasingly favor targeted, maintenance-based therapies over repeated steroid interventions.
Recent Developments
• 2023: Roche began clinical trials for tocilizumab in refractory non-infectious uveitis.
• 2024: Santen Pharmaceutical launched a new corticosteroid-sparing eye drop in Asia.
• 2024: Sun Pharma announced expansion of its ophthalmic biologic pipeline targeting uveitis and scleritis.
• 2024: Academic collaborations in the U.S. and Europe introduced AI-based grading systems for uveitis severity scoring.
Expert Insight
"With biologic therapies, we're no longer simply suppressing inflammation-we're targeting its root cause. Combined with big-data analytics, the uveitis landscape is evolving toward precision population health,"
- Dr. Hiroshi Tanaka, Professor of Ophthalmic Immunology, Kyoto University.
Conclusion
The Uveitis Market is entering a new era of precision ophthalmology driven by biologics, data analytics, and global awareness.
As epidemiological studies refine the patient pool and digital tools enable early intervention, the next decade will see major reductions in vision loss worldwide.
Ongoing investments in AI diagnostics, biologic access, and patient-registry integration will continue to define growth through 2034.
This report is also available in the following languages : Japanese (ぶどう膜炎患者プール分析、市場), Korean (포도막염 환자 풀 분석, 시장), Chinese (葡萄膜炎患者群体分析,市场), French (Analyse du marché des patients atteints d'uvéite), German (Analyse des Patientenpools bei Uveitis, Markt), and Italian (Analisi del pool di pazienti con uveite, mercato), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72310
Our More Reports:
Dravet Syndrome (DS) Market
https://exactitudeconsultancy.com/reports/72087/dravet-syndrome-ds-market
Generalized Myasthenia Gravis (gMG) Market
https://exactitudeconsultancy.com/reports/72089/generalized-myasthenia-gravis-gmg-market
Spinocerebellar Ataxia (SCA) Market
https://exactitudeconsultancy.com/reports/72095/spinocerebellar-ataxia-sca-market
Spinal Cord Injury (SCI) - Epidemiology forecast- 2034 Market
https://exactitudeconsultancy.com/reports/72122/spinal-cord-injury-sci-epidemiology-forecast-2034-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Uveitis Market: Growing Patient Pool and Biologic Advances Drive Growth to 2034 here
News-ID: 4259098 • Views: …
More Releases from Exactitude Consultancy
Anesthesia & Respiratory Devices Market Set for Sustained Growth Through 2034: E …
Introduction
Pune, India - November 2025 - Exactitude Consultancy, a leading provider of market research and consulting services, announces the release of its latest study on the Global Anesthesia & Respiratory Devices Market. The report projects robust growth through 2034, driven by the rise in surgical procedures, the growing prevalence of chronic respiratory conditions, and continuous innovations in anesthesia and respiratory care technologies.
Download Full PDF Sample Copy of Market Report @…
Persistent Epithelial Defect Market: Regenerative and Biologic Therapies Drive G …
Subheadline:
Rising incidence of corneal surface injuries, adoption of regenerative eye therapies, and innovation in biologic eye drops are driving steady expansion of the persistent epithelial defect (PED) market worldwide.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72290
Introduction
The Persistent Epithelial Defect (PED) Market is gaining clinical and commercial importance as ophthalmology embraces regenerative medicine, biologic formulations, and advanced wound-healing technologies.
Valued at USD 210 million in 2024, the market is projected…
Scleritis Market: Biologic Advances and Early Diagnosis Drive Growth to 2034
Subheadline:
Growing autoimmune disease awareness, biologic drug adoption, and precision ophthalmology tools are driving steady growth in the global scleritis treatment market.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72281
Introduction
The Scleritis Market is witnessing gradual but significant growth as advances in biologic drugs, early autoimmune diagnostics, and ocular immunology research reshape disease management strategies.
Valued at USD 270 million in 2024, the market is projected to reach USD 490 million by…
Mantle Cell Lymphoma Market: Targeted and Cell Therapies Drive Growth to 2034
Subheadline:
Breakthroughs in BTK inhibitors, CAR-T therapy expansion, and growing clinical trial activity are driving the global mantle cell lymphoma (MCL) market toward a transformative decade.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72262
Introduction
The Mantle Cell Lymphoma (MCL) Market is experiencing rapid innovation as targeted therapy advancements, immuno-oncology research, and cell-based treatment approvals reshape the hematologic cancer landscape.
Valued at USD 3.1 billion in 2024, the global market is projected to…
More Releases for Uveitis
Uveitis Market : An Overview Report
Introduction:
Uveitis is an inflammatory condition affecting the uvea, the middle layer of the eye. It can lead to vision impairment or even blindness if left untreated. Uveitis is categorized into different types, including anterior, intermediate, posterior, and panuveitis, depending on the part of the eye affected. The condition can be caused by infections, autoimmune diseases, or trauma. With increasing cases of autoimmune disorders and infectious diseases, the prevalence of uveitis…
Uveitis Treatment Market Size, Share | Trend 2030
Exclusive Report by Ameco Research: Uveitis Treatment Market Size Projected to Reach USD 2 Billion by 2030, Growing at 6% CAGR
Ameco Research is proud to announce the launch of its latest market research report, Uveitis Treatment Market. This comprehensive report provides in-depth analysis and insights into the current market trends and future projections in the Industry/Market Segment. Ameco Research has been at the forefront of providing quality market research…
Uveitis - Drug Pipeline Landscape, 2022
New York, Global Insight Services have recently published a report on Uveitis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Uveitis is an inflammation of the eye which damages the part of the eye called the uvea and affects other parts of the eyes which causes pain to the eyes. There are 4 types of…
Uveitis - Drug Pipeline Landscape, 2022
Global Insight Services have recently published a report on Uveitis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Uveitis is an inflammation of the eye which damages the part of the eye called the uvea and affects other parts of the eyes which causes pain to the eyes. There are 4 types of uveitis based…
Japan Industry Statistics of Uveitis Treatment
Global Uveitis Treatment Market: Overview
Uveitis, an autoimmune eye disease, is considered rare for just around 38 in 100,000 people are afflicted by it. Because of this, it is often overlooked. Patients afflicted by uveitis are often referred to an expert after much delay on account of less awareness about the eye malady. This delays timely diagnosis and results in irreversible damage to various ocular structures.
Read Report Overview: https://www.transparencymarketresearch.com/uveitis-treatment-market.html
As per Cochrane,…
Uveitis Treatment Market Analysis of Top industry Scenario
Global Uveitis Treatment Market report it provides a vital recent industry data which covers in general market situation along with future scenario for industry around the Globe. It also consists of major data along with forecasts of a global market along with clear presentation of diagrams (charts and tables).
According to a new report published by Allied Market Research, titled, "Uveitis Treatment Market by Drug Class (Anti-inflammatory, Antimicrobial Drugs, Immunotherapy &…
